23andMe Holding Bilan de santé

Santé financière contrôle des critères 4/6

23andMe Holding possède un total de capitaux propres de $101.9M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $318.9M et de $217.0M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$126.60m
Fonds propres	US$101.93m
Total du passif	US$217.01m
Total des actifs	US$318.94m

Mises à jour récentes de la santé financière

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Apr 16

Recent updates

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Apr 16

Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

Mar 02

23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

Aug 11

23andMe Q1 2023 Earnings Preview

Aug 07

23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive

Jun 15

23andMe: A Genetics Innovator Positioned For Growth

Feb 19

Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

Feb 18

23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive

Nov 21

23andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains

Oct 03

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ME ( $188.8M ) dépassent ses passifs à court terme ( $152.8M ).

Passif à long terme: Les actifs à court terme de ME ( $188.8M ) dépassent ses passifs à long terme ( $64.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: ME est sans dette.

Réduire la dette: ME n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ME dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ME dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 1.2 % chaque année

23andMe Holding Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

23andMe Holding Regains Compliance with Nasdaq Minimum Bid Price Requirement and Corporate Governance Requirements

23andMe Holding Co. Receives A Deficiency Letter Regarding Nasdaq Listing Rule 5605

The Nasdaq Stock Market LLC Grants 23andMe Holding an Additional 180 Days, or Until November 4, 2024, to Regain Compliance with the Minimum Bid Price Requirement Under Nasdaq Marketplace Rule 5550(a)(2)

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

23andMe Holding Receives Deficiency Letter from Nasdaq Regarding Non-Compliance Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1)

23andMe Holding Receives Deficiency Letter from Nasdaq Regarding Non-Compliance Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1)

Recent updates

23andMe Holding Co. Announces Reduce Overall Headcount

23andMe Holding Co. to Report Q2, 2025 Results on Nov 12, 2024

23andMe Holding Regains Compliance with Nasdaq Minimum Bid Price Requirement and Corporate Governance Requirements

23andMe Holding Co. Announces Board Appointments

23andMe Holding Co. Receives A Deficiency Letter Regarding Nasdaq Listing Rule 5605

23andMe Holding Co. Announces Board Resignations

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

Anne Wojcicki delivered a non-binding indication of interest to acquire remaining 99.7% stake in 23andMe Holding Co. (NasdaqCM:ME) for approximately $190 million.

23andMe Holding Co. to Report Q1, 2025 Results on Aug 08, 2024

23andMe Holding Co., Annual General Meeting, Aug 28, 2024

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, Targeting CD200R1, at the 2024 ASCO Annual Meeting

23andMe Holding Co. Reports Unaudited Consolidated Goodwill Impairment for the Fourth Quarter Ended March 31, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

23andMe Holding Co. to Report Q4, 2024 Results on May 23, 2024

The Nasdaq Stock Market LLC Grants 23andMe Holding an Additional 180 Days, or Until November 4, 2024, to Regain Compliance with the Minimum Bid Price Requirement Under Nasdaq Marketplace Rule 5550(a)(2)

23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting

New major risk - Share price stability

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

23andMe Holding Co. Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Insider notifies of intention to sell stock

Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

23andMe Holding Co. Reports Goodwill Impairment for the Third Quarter Ended December 31, 2023

23andMe Holding Co. Announces U.S. Food and Drug Administration Clears Investigational New Drug Application for 23ME-01473

23andMe Holding Co. to Report Q3, 2024 Results on Feb 07, 2024

23andMe Holding Co. Provides Update on Class Action

23andMe Holding Co. Provides Update on Class Action

23andMe Holding Co. Announces Further Expansion of 23ME-00610 Phase 1/2a Clinical Trial in Advanced Neuroendocrine and Ovarian Cancer Patient Cohorts

Insider notifies of intention to sell stock

23andMe Holding Receives Deficiency Letter from Nasdaq Regarding Non-Compliance Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1)

23andMe Holding Receives Deficiency Letter from Nasdaq Regarding Non-Compliance Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1)

23Andme Holding Co. Reaffirms Earnings Guidance for the Year 2024

Price target decreased by 20% to US$3.58

High number of new and inexperienced directors

23andMe Holding Co. Announces Updated Safety and Preliminary Efficacy Data from the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

23andMe Holding Co. to Report Q2, 2024 Results on Nov 08, 2023

23Andme Holding Co. Grants New FDA Clearance to Report Additional BRCA Variants

23andMe Holding Co. Revises Earnings Guidance for the Year Ending March 31, 2024

Insider notifies of intention to sell stock

23andMe Holding Co., Annual General Meeting, Sep 06, 2023

23andMe Holding Co. to Report Q1, 2024 Results on Aug 08, 2023

We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

Insider notifies of intention to sell stock

23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

Price target decreased by 12% to US$4.50

Price target decreased by 9.9% to US$5.13

23andMe Holding Co. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings: EPS exceeds analyst expectations

23andMe Holding Co. to Report Q4, 2023 Results on May 25, 2023

23Andme Holding Co. Announces the Appointment of Reza Afkhami as Chief Corporate Development Officer

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

23andMe Holding Co. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2023

23andMe Holding Co. to Report Q3, 2023 Results on Feb 08, 2023

Insider notifies of intention to sell stock

Director recently sold US$60k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

23andMe Holding Co. Reconfirms Earnings Guidance for the Full Year Ending March 31, 2023

23anMe Granted New FDA Clearance to Provide Interpretive Drug Information for A Commonly Prescribed Cholesterol Medication

23andMe Holding Co. to Report Q2, 2023 Results on Nov 07, 2022

23andMe: Disappointing Results Could Mean Potential Acquisition Target

Daniel Chu Joins 23andMe Holding Co. as Chief Product Officer

23andMe: Treacherous Path To Profitability

23andMe Holding Co. Announces CFO Changes

23andMe drops 8% as CFO resigns

23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

23andMe Holding Co. Provides Earnings Guidance for 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

23andMe Q1 2023 Earnings Preview

23andMe Holding Co. to Report Q1, 2023 Results on Aug 08, 2022